News
-
-
PRESS RELEASE
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
Formycon AG invites to conference call for 2023 financial year results and announces participation in upcoming international investor conferences -
-
PRESS RELEASE
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
Formycon reports strong preliminary results for the financial year 2023, with a Group revenue increase of 83% to €77.7 million, positive Group EBITDA achieved, and a new key financial performance indicator introduced -
-
PRESS RELEASE
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024 -
-
PRESS RELEASE
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases -
-
PRESS RELEASE
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options
-
Hour One Enables Life-Like Cinematic Avatar of NVIDIA CEO Jensen Huang at Computex 2024
-
Introducing Red Kale Medley, a Mix of Baby Red and Green Kale Complemented by B&W’s Signature Watercress
-
Fungies Mushroom Gummies Announces Major Retail Expansion and Availability at Walmart
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
EQS-Adhoc: Vulcan Energy Resources Limited: Vulcan Energy signs agreements with CIMIC Group, Hancock Prospecting and Victor Smorgon Group for a total equity investment of EUR 40 million
-
ROAD TO COLOGNE 2024 - SAILUN on the home straight to THE TIRE COLOGNE
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business